These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 1356081)
1. Powder coating mixture of a novel anxiolytic, Y-23684: dissolution characteristics and bioavailability. Samemoto H; Yamada I; Yata T; Ogawa K Chem Pharm Bull (Tokyo); 1992 Apr; 40(4):1007-10. PubMed ID: 1356081 [TBL] [Abstract][Full Text] [Related]
2. Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68. Chen Y; Zhang GG; Neilly J; Marsh K; Mawhinney D; Sanzgiri YD Int J Pharm; 2004 Nov; 286(1-2):69-80. PubMed ID: 15501003 [TBL] [Abstract][Full Text] [Related]
3. Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique. Cao QR; Liu Y; Xu WJ; Lee BJ; Yang M; Cui JH Int J Pharm; 2012 Sep; 434(1-2):325-33. PubMed ID: 22688251 [TBL] [Abstract][Full Text] [Related]
4. Novel electrosprayed nanospherules for enhanced aqueous solubility and oral bioavailability of poorly water-soluble fenofibrate. Yousaf AM; Mustapha O; Kim DW; Kim DS; Kim KS; Jin SG; Yong CS; Youn YS; Oh YK; Kim JO; Choi HG Int J Nanomedicine; 2016; 11():213-21. PubMed ID: 26834471 [TBL] [Abstract][Full Text] [Related]
5. Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies. Van Gyseghem E; Pendela M; Baert L; Rosier J; Van 't Klooster G; De Man H; Bouche MP; Schueller L; Van Remoortere P; Wigerinck P; Adams E; Hoogmartens J; Van den Mooter G Eur J Pharm Biopharm; 2008 Nov; 70(3):853-60. PubMed ID: 18657611 [TBL] [Abstract][Full Text] [Related]
6. Effect of magnesium carbonate on the solubility, dissolution and oral bioavailability of fenofibric acid powder as an alkalising solubilizer. Kim KS; Kim JH; Jin SG; Kim DW; Kim DS; Kim JO; Yong CS; Cho KH; Li DX; Woo JS; Choi HG Arch Pharm Res; 2016 Apr; 39(4):531-538. PubMed ID: 26992922 [TBL] [Abstract][Full Text] [Related]
7. Development of novel sibutramine base-loaded solid dispersion with gelatin and HPMC: physicochemical characterization and pharmacokinetics in beagle dogs. Lim HT; Balakrishnan P; Oh DH; Joe KH; Kim YR; Hwang DH; Lee YB; Yong CS; Choi HG Int J Pharm; 2010 Sep; 397(1-2):225-30. PubMed ID: 20637849 [TBL] [Abstract][Full Text] [Related]
8. Development of novel ibuprofen-loaded solid dispersion with improved bioavailability using aqueous solution. Park YJ; Kwon R; Quan QZ; Oh DH; Kim JO; Hwang MR; Koo YB; Woo JS; Yong CS; Choi HG Arch Pharm Res; 2009 May; 32(5):767-72. PubMed ID: 19471892 [TBL] [Abstract][Full Text] [Related]
9. Improvement of dissolution rate and oral bioavailability of a sparingly water-soluble drug, (+/-)-5-[[2-(2-naphthalenylmethyl)-5-benzoxazolyl]-methyl]- 2, 4-thiazolidinedione, in co-ground mixture with D-mannitol. Kubo H; Mizobe M Biol Pharm Bull; 1997 Apr; 20(4):460-3. PubMed ID: 9145232 [TBL] [Abstract][Full Text] [Related]
10. Applying a novel electrostatic dry powder coating technology to pellets. Yang Q; Ma Y; Zhu J Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):118-24. PubMed ID: 26478275 [TBL] [Abstract][Full Text] [Related]
11. Preformulation characterization and in vivo absorption in beagle dogs of JFD, a novel anti-obesity drug for oral delivery. Fan Y; Yang M; Wang Y; Li Y; Zhou Y; Chen X; Shan L; Wei J; Gao C Drug Dev Ind Pharm; 2015 May; 41(5):801-11. PubMed ID: 24694186 [TBL] [Abstract][Full Text] [Related]
12. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55. Sauer D; Zheng W; Coots LB; McGinity JW Eur J Pharm Biopharm; 2007 Sep; 67(2):464-75. PubMed ID: 17451929 [TBL] [Abstract][Full Text] [Related]
13. Spray drying of a poorly water-soluble drug nanosuspension for tablet preparation: formulation and process optimization with bioavailability evaluation. Sun W; Ni R; Zhang X; Li LC; Mao S Drug Dev Ind Pharm; 2015 Jun; 41(6):927-33. PubMed ID: 24785575 [TBL] [Abstract][Full Text] [Related]
14. [Dissolution properties and bioavailability of ground mixture of N,N-dimethylcarbamoylmethyl alpha, 2-dimethyl-5H-[1]benzopyrano[2,3-b]-pyridine-7-acetate with various pharmaceutical ingredients]. Yamada I; Kawata M; Shibata T; Ogawa K; Yokobe T Yakugaku Zasshi; 1989 Dec; 109(12):932-7. PubMed ID: 2630636 [TBL] [Abstract][Full Text] [Related]
15. Studies on the synthesis of condensed pyridazine derivatives. IV. Synthesis and anxiolytic activity of 2-aryl-5,6-dihydro-(1)benzothiepino[5,4- c]pyridazin-3(2H)-ones and related compound. Nakao T; Obata M; Kawakami M; Morita K; Tanaka H; Morimoto Y; Takehara S; Yakushiji T; Tahara T Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2556-63. PubMed ID: 1687209 [TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical and pharmacokinetic characteristics of different types of fenofibrate nanocrystals prepared by different bottom-up approaches. Zhang H; Meng Y; Wang X; Dai W; Wang X; Zhang Q Drug Deliv; 2014 Dec; 21(8):588-94. PubMed ID: 24320001 [TBL] [Abstract][Full Text] [Related]
17. Enhancement of dissolution rate and oral absorption of a poorly water-soluble drug, K-832, by adsorption onto porous silica using supercritical carbon dioxide. Miura H; Kanebako M; Shirai H; Nakao H; Inagi T; Terada K Eur J Pharm Biopharm; 2010 Oct; 76(2):215-21. PubMed ID: 20603215 [TBL] [Abstract][Full Text] [Related]
18. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. Jinno J; Kamada N; Miyake M; Yamada K; Mukai T; Odomi M; Toguchi H; Liversidge GG; Higaki K; Kimura T J Control Release; 2006 Mar; 111(1-2):56-64. PubMed ID: 16410029 [TBL] [Abstract][Full Text] [Related]
19. Enhanced dissolution and oral bioavailability of nifedipine by spontaneous emulsifying powders: effect of solid carriers and dietary state. Weerapol Y; Limmatvapirat S; Jansakul C; Takeuchi H; Sriamornsak P Eur J Pharm Biopharm; 2015 Apr; 91():25-34. PubMed ID: 25615879 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of oral bioavailability and pharmacological effect of 1-(3,4-dimethoxyphenyl)-2,3-bis(methoxycarbonyl)-4-hydroxy-6,7,8- trimethoxynaphthalene (TA-7552), a new hypocholesterolemic agent, by micronization in co-ground mixture with D-mannitol. Kubo H; Osawa T; Takashima K; Mizobe M Biol Pharm Bull; 1996 May; 19(5):741-7. PubMed ID: 8741587 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]